Related Experiment Video
Updated: Jan 14, 2026
A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
Published on: July 3, 2013
Multigene RNAi Technology to Treat Cancer: Harnessing Synergistic Gene Regulation to Combat Evolving Cancer
Swetha Vaishnavi1, Chandra S Bhatt1, Satheesh Ellipilli1
1Chemical Biology Lab, Department of Chemistry, School of Engineering and Sciences, SRM University-AP, Amaravati 522240, India.
Abstract:
Recent advancements in the cellular and molecular understanding of cancer biology have significantly increased the probability of managing uncontrolled cancer cell proliferation. Advancements in combinational drug delivery at a minimal dose in tumor reduction are providing alternative therapeutic approaches in the clinical management of different cancer types over traditional anticancer treatment regimes. In contrast, an emerging paradigm in RNA interference (RNAi)-based therapeutics has been under study for a few decades to overcome the limitation of conventional cancer therapy by targeting cancer at its genetic and epigenetic levels. The intricate crosstalk among multifaceted signaling and effector pathways in cancer has long been recognized, and the adaptability of this network to evade single-target interventions using RNAi in cancer treatment is driving the advancement of combinational RNAi-based therapies. Therefore, researchers are exploring combinations of small interfering RNA (siRNA), microRNA (miRNA), and other small RNAs to silence multiple genes simultaneously, offering a potential solution to treat ever-evolving cancer by overcoming resistance mechanisms of cancer cells. This review endeavors to bring attention to the rationale of combinational cancer therapy using RNAi-based therapeutics for effective cancer treatment. Here, we provide a comprehensive analysis of multigene targets designed for blocking different tumor-associated cellular functions. Our systematic analysis of preclinical tumor inhibition studies shows that combinational RNAi therapy outperforms by reducing the average tumor volume to 22.85% compared to that of 54.75% when treated with single RNAi therapies. Finally, we highlight the challenges and future perspectives inherent in the formulation of combinational RNAi-based therapies. Overall, this review underscores the potential of combinational RNAi-based therapy and may serve as a reference for researchers in the selection of precise and efficient RNAi combinations, promoting ongoing advancements in cancer treatment.
Insights
Combinational RNA interference (RNAi) therapies silence multiple cancer-related genes, overcoming resistance and improving tumor reduction. This approach significantly outperforms single RNAi treatments in preclinical studies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Cancer treatment faces challenges from uncontrolled cell proliferation and resistance to conventional therapies.
- RNA interference (RNAi) therapeutics offer a novel approach by targeting cancer at genetic and epigenetic levels.
- The complexity of cancer signaling networks necessitates strategies beyond single-target interventions.
Purpose of the Study:
- To review the rationale and efficacy of combinational RNAi-based cancer therapy.
- To analyze multigene targets for blocking tumor-associated cellular functions.
- To highlight challenges and future directions in combinational RNAi therapeutics.
Main Methods:
- Systematic analysis of preclinical studies on combinational RNAi therapy.
- Evaluation of multigene silencing strategies against cancer pathways.
- Comparison of tumor volume reduction between single and combinational RNAi treatments.
Main Results:
- Combinational RNAi therapy reduced average tumor volume by 22.85%.
- Single RNAi therapies resulted in an average tumor volume reduction of 54.75%.
- Combinational approaches demonstrated superior efficacy in preclinical tumor inhibition.
Conclusions:
- Combinational RNAi therapy presents a promising strategy for effective cancer treatment by overcoming resistance mechanisms.
- Multigene silencing via RNAi offers a potential solution for managing complex and evolving cancers.
- Further research into formulation and precise selection of RNAi combinations is crucial for clinical advancement.
More Related Videos
09:40Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019
07:23Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
Related Concept Videos
02:15Experimental RNAi
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:56Treatment Resistant Cancers
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...